Company intelligence / Profile preview
HemoShear Therapeutics
Charlottesville, Virginia, United Stateshemoshear.com ↗
- Ownership
- Private
- Employees
- ~40
- Development stage
- Other
01
Overview
HemoShear’s lead candidate HST5040 has completed or is completing a Phase 2 study in MMA and PA. The compound has received Orphan Drug, Fast Track, and Rare Pediatric Disease designations from the FDA. The company also has preclinical programs targeting cholestasis disorders and hepatitis D with novel small molecules. Collaborations have validated their REVEAL-Tx™ platform in NASH and gout.
- Therapeutic areas
- GastroenterologyInfectious DiseasesMetabolic DisordersRheumatology
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
Takeda Pharmaceutical Company (NASH)Horizon Therapeutics plc. (gout)Suvretta Capital as major investor/sponsor of clinical studies
Beyond the preview
Go deeper on HemoShear Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HemoShear Therapeutics.